I S Medident Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -39.35%
- Profit Growth -35.09%
- Ebitda -35.09%
- Net Worth 7.66%
- Total Assets -35.48%
About I S Medident
I S Medident Private Limited (ISMPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 June 2015 (Nine years and eight months 18 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Imran Ahamad, Mehraj Ahmad, and Sriniwasa Athanarian serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33110DL2015PTC281238
- Company No.
281238
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Jun 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does I S Medident Private Limited offer?
I S Medident Private Limited offers a wide range of products and services, including Oils, Grease & Lubricants, Lubricating Oil, Dentist Tools, Equipment & Supplies, Dental Instruments, Dental Handpieces, Dental Equipment, Dental Implant Kit, Physiodispenser, Lubricants, Lubricant Spray.
Who are the key members and board of directors at I S Medident?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Imran Ahamad  | Director | 08-Jun-2015 | Current |
| Mehraj Ahmad | Director | 08-Jun-2015 | Current |
Sriniwasa Athanarian  | Director | 22-Jun-2015 | Current |
Financial Performance of I S Medident.
I S Medident Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 39.35% decrease. The company also saw a substantial fall in profitability, with a 35.09% decrease in profit. The company's net worth moved up by a moderate rise of 7.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of I S Medident?
Unlock access to I S Medident's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at I S Medident?
Unlock and access historical data on people associated with I S Medident, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of I S Medident, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped I S Medident's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.